Clasp Therapeutics

Clasp Therapeutics Pioneers Precision Immuno-Oncology by Targeting Tumor-Specific Oncogenic Driver Mutations Common in Hard-to-Treat Cancers with Next-Generation T Cell Engagers (TCE). Clasp's platform identifies neoantigens associated with mutations and develops TCEs that selectively bind to HLA-presented peptides derived from these oncogenic drivers. These innovative TCEs can direct all types of T cells to destroy tumors. With their unique properties, Clasp’s TCEs can be applied across various cancers, addressing significant unmet needs.